Thromb Haemost 2017; 117(11): 2209-2211
DOI: 10.1160/TH17-07-0474
Letter to the Editor
Schattauer GmbH Stuttgart

Apixaban Auto-intoxication: Toxicokinetics and Coagulation Tests

L. Mast
,
R.J. Verheul
,
R. Reijnen
,
R.C.J.M. van Rossen
,
J.W.P.M. Overdiek
,
E.B. Wilms
Further Information

Publication History

10 July 2017

07 August 2017

Publication Date:
30 November 2017 (online)

Dear Sirs,

Apixaban is a direct oral anticoagulant (DOAC) that acts on the coagulation cascade by direct factor Xa inhibition. It is currently approved for the prevention and treatment of venous thromboembolism and for the prevention of stroke and systemic embolism in atrial fibrillation patients.[1] Two case reports have described an apixaban overdose thus far,[2] [3] and little is known about apixaban toxicokinetics. We present an apixaban auto-intoxication with corresponding toxicokinetics and coagulation tests.